Pfizer-BioNTech COVID-19 vaccine receives FDA emergency use authorisation for children 6 months through 4 years of age

Pfizer

17 June 2022 - In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 vaccine elicited a strong immune response in this age group.

Pfizer and BioNTech today announced the U.S. FDA granted emergency use authorisation of the Pfizer-BioNTech COVID-19 Vaccine as a three 3 µg dose series for children 6 months through 4 years of age (also referred to as 6 months to less than 5 years of age). 

The 3 µg dose was carefully selected as the preferred dose for children under 5 years of age based on safety, tolerability, and immunogenicity data.

Read Pfizer press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , US , Vaccine , Paediatrics , COVID-19